May 2012 
Volume 42  Number 5
Pages 16 - 16
  PDF Version Available!

The FDA has issued updated recommendations for dangerous drug-drug interactions between protease inhibitors used to treat HIV infection or hepatitis C virus (HCV) infection and certain HMG-CoA reductase inhibitors (statins), used to treat dyslipidemia. When used with statins, protease inhibitors may increase serum statin levels and increase the risk for myopathy. The most serious form of myopathy, rhabdomyolysis, can lead to renal failure.The labels for both drug types have been updated to include reliable information about the drug-drug interactions. The labels now include dosing information for statins that may be safely coadministered with HIV or HCV protease inhibitors.Source: FDA Drug Safety Communication: interactions between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase the risk of muscle injury. http://www.fda.gov/Drugs/DrugSafety/ucm293877.htm .A recent study involved 184 patients in a vegetative or minimally conscious state following severe

Purchase Now !

To purchase this item, follow the instructions below. If you’re not already logged in, be sure to enter your login information below to ensure that your item is saved to your File Drawer after you purchase it.

Not a member? Join now for Free!

1) If you're not already logged in, enter your information below to save this item in your File Drawer for future viewing.

User name:


Forgot your user name or password?
2)  If you have a coupon or promotional code, enter it
here.(If not, just click Continue.

Digital Coupon: (optional)

3)  Click Continue to go to the next screen, where
you'll enter your payment details.

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events